Health Trials

Lymphoma, Extranodal NK-T-Cell

2

Review clinical trials related to Lymphoma, Extranodal NK-T-Cell. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Participants needed: 18
Trial details
Phase: Phase 2Age: 14-75Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Aug 27, 2024
Eligibility criteria

Confirmed histological diagnosis of NKTCL nasal type [+10]

Confirmed histological diagnosis of aggressive NK cell leukemia [+11]

Read more
Status: Recruiting

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.

Participants needed: 34
Trial details
Phase: Phase 2Age: 19-65Biological sex: AllType: InterventionalSponsor: Keimyung University Dongsan Medical CenterUpdated: Aug 18, 2022Locations: 2
Eligibility criteria

Age 19 - 65 [+17]

Adult T cell leukemia/lymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+... [+14]

Read more